Skip to content

Clinical Study to Check the Efficacy and Safety of Arshtab-h70 in the Management of Primary Hemorrhoids

An Open-label, Single-arm Clinical Study to Evaluate the Efficacy and Safety of Arshtab-h70 in the Management of Primary Hemorrhoids - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080485
Enrollment
20
Registered
2025-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K649- Unspecified hemorrhoids

Interventions

None listed

Sponsors

Sudhatatva Pharmacy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Symptomatic primary hemorrhoids, Grades I-II by direct anoscopic visualization (anoscopic visualization not required if Grade determined by colonoscopy within 21 days prior to Day 1). 2 Bleeding from hemorrhoids for two consecutive days prior to randomization (Day 1). 3 The patient having Bleeding hemorrhoids, Pain in anal region due to piles complication (i.e. Inflammation, thrombosis), prolaps, itching, constipation two days prior to randomization (Day 1) will be selected for this clinical study. 4 For female patients cause of bleeding due to menses should be ruled out. 5 Able to attempt bowel movements daily (defined as trying to have a bowel movement while sitting on the toilet for at least a few minutes, at least once daily) 6 Able to communicate adequately with the investigator and to comply with the requirements for the entire study. 7 Capable of and freely willing to provide written informed consent prior to participating in the study. 8 Signed informed consent prior to any study-mandated procedure. 9 Willing to comply with daily protocol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Reduction in symptoms scores at endpoint as compared to baseline values in symptoms of Bleeding per rectum, Size of pile mass.Timepoint: Follow-up visits will be scheduled on the 7th, 15th, and 21st days after enrollment. A window period of 2 days will be allowed for each follow-up visit.

Secondary

MeasureTime frame
Reduction in symptoms scores at endpoint as compared to baseline values in symptoms of Protrusion of mass, Constipation, Tenderness, Pain.Timepoint: Follow up visits will be scheduled at 7th, 15th, & 21st days after enrollment. A window period of 2 days will be allowed for each follow up visit.

Countries

India

Contacts

Public ContactDr Amit A Paliwal

Dr D Y Patil College of Ayurved and Research Centre Pimpri Pune

bhagyashri.chakole@dpu.edu.in90965 87493

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026